Get the Stockscreener App
34.52
2.79%
-0.99
After Hours:
34.45
-0.07
-0.20%
Vera Therapeutics Inc stock is traded at $34.52, with a volume of 1.32M.
It is down -2.79% in the last 24 hours and down -15.52% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$35.51
Open:
$35.6
24h Volume:
1.32M
Relative Volume:
1.12
Market Cap:
$2.48B
Revenue:
-
Net Income/Loss:
$-299.62M
P/E Ratio:
-7.4015
EPS:
-4.6639
Net Cash Flow:
$-241.73M
1W Performance:
-6.98%
1M Performance:
-15.52%
6M Performance:
+43.24%
1Y Performance:
+35.21%
1-Day Range:
$34.04
$36.01
1-Week Range:
$34.04
$36.80
52-Week Range:
$18.76
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
34.52 | 2.55B | 0 | -299.62M | -241.73M | -4.6639 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Understanding Momentum Shifts in (VERA) - Stock Traders Daily
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference - The Manila Times
Vera Therapeutics to present May 13 at Bank of America health conference - Stock Titan
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics (VERA) to Release Earnings on Tuesday - MarketBeat
HC Wainwright & Co. Maintains Vera Therapeutics (VERA) Buy Recommendation - MSN
Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans - MSN
Vera Therapeutics announces $200M public offering - MSN
When Will Vera Therapeutics, Inc. (NASDAQ:VERA) Turn A Profit? - 富途牛牛
Avoiding Lag: Real-Time Signals in (VERA) Movement - Stock Traders Daily
Why Vera Therapeutics Stock Rocked the Market on Tuesday - MSN
VERA (Vera Therapeutics Inc.) drops 2.78% after reporting a wider than expected Q4 2025 loss that missed analyst estimates.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Vera Therapeutics CEO Sells Over 22,000 Shares - National Today
Vera Therapeutics Stock Earns 'Moderate Buy' Rating from Analysts - National Today
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vera Therapeutics CEO Sells Over $1 Million in Stock - National Today
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock By Investing.com - Investing.com Australia
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock - Investing.com
Vera Therapeutics (NASDAQ:VERA) CEO Sells $1,010,991.55 in Stock - MarketBeat
Vera Therapeutics Insider Sold Shares Worth $1,011,051, According to a Recent SEC Filing - marketscreener.com
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Polycythemia Vera Market: Rapid Increment Driven by Innovation - openPR.com
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛
Vertex Sues Former Exec To Block Move To Rival - Law360
VERA (NASDAQ: VERA) director sells 16,925 shares for $710,577.51 — Form 144 - Stock Titan
AMI Asset Management Corp Makes New $1.44 Million Investment in Vera Therapeutics, Inc. $VERA - MarketBeat
Panic Selling: Is Vera Therapeutics Inc vulnerable to short sellersQuarterly Risk Review & Verified Short-Term Trading Plans - baoquankhu1.vn
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily
Vera Therapeutics Announces Inducement Grants - National Today
Vera Therapeutics (VERA) Valuation Check After Recent Share Price Rebound - Sahm
Risk Check: Does Vera Therapeutics Inc align with a passive investing strategyTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Vera Therapeutics stock rises after crossing above key SMA - Intellectia AI
Published on: 2026-04-11 13:37:36 - baoquankhu1.vn
Can Vera Therapeutics Inc deliver consistent EPS growth2026 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
Vera Therapeutics Grants Inducement Awards to New Employees Under 2024 Inducement Plan - Quiver Quantitative
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.1%What's Next? - MarketBeat
Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge - Yahoo Finance
[ARS] Vera Therapeutics, Inc. SEC Filing - Stock Titan
Board of Vera Therapeutics (VERA) seeks votes on directors, auditor and say-on-pay - Stock Titan
Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge? - Sahm
JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA - MarketBeat
BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating - MSN
Vera Therapeutics Inc. (VERA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vera Therapeutics Adds Experienced Legal Chief As Shares Trade Below Targets - Sahm
Behavioral Patterns of VERA and Institutional Flows - Stock Traders Daily
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):